Editor - Shayne C Gad | Gad Consulting Services | 24057

World Journal of Pharmacology and Toxicology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Shayne C Gad

Shayne C Gad
Shayne C Gad
Gad Consulting Services
United States of America


Shayne C. Gad, B.S. (Whittier College, Chemistry and Biology, 1971) and after active duty service in U.S. Navy, Ph.D. in Pharmacology/Toxicology (Texas, 1977) DABT, Principal of Gad Consulting Services, a twenty-four year old consulting firm with nine employees and more than 500 clients worldwide in the pharmaceutical and medical device industries. Past President of the American College of Toxicology, the Roundtable of Toxicology Consultants and three of SOT’s specialty sections, and recipient of the American College of Toxicology Lifetime Contribution Award in 2008. Served on Council, Membership, Program, and Animals in Research committees for ACT, multiple committees in SOT, and currently on the regulatory opinions committee of the Society of Toxicologic Pathologists. Previously at CMIR Chemical Hygiene Fellowship, Allied Chemical, Searle, Becton Dickinson and Synergen. He has authored or edited 49 published books and more than 350 chapters, articles and abstracts in the fields of toxicology, statistics, pharmacology, drug and device development and safety assessment. He has more than 39 years of broad based experience in regulatory toxicology, drug and device development, statistics and risk assessment, and has specific expertise in neurotoxicology, in vitro methods, cardiovascular toxicology, inhalation toxicology, immunotoxicology, risk assessment and genotoxicology. Grant reviewer for EPA, CAAT, NIH, and Canadian Health. He has direct involvement in the preparation of INDs (111 successfully to date), NDA, PLA, ANDA, 510(k), IDE, CTD, clinical data bases for phase 1 and 2 studies, and PMAs. Served as the COO of two pharmaceutical companies while a consultant.

Research Interest

Neurotoxicology,cardiovascular toxicology, inhalation toxicology, immunotoxicology, risk assessment and genotoxicology